4 research outputs found
Detection of derivative 9 deletion by BCR-ABL fluorescence in-situ hybridization signal pattern to evaluate treatment response in CML patients
Background: To evaluate prognostic effect of submicroscopic deletions involving breakage and fusion points of the derivative chromosome 9 and 22 in chronic myeloid leukemia in untreated patients and their follow up samples to correlate with disease outcome. Methods: The study included 78 pretreatment (PT) samples from CML patients and 90 follow-up samples, classified as complete responders (CR, n=33), nonresponders (NR, n =54), and partial responder (PR, n=3) depending on the treatment status of the follow-up samples. Karyotype analysis was performed on metaphases obtained through short term cultures of bone marrow and blood. Detection of BCR-ABL fusion gene was performed using dual color dual fusion (D-FISH) translocation probes. Results: BCR-ABL fusion gene detection by D-FISH showed ABL-BCR deletion on derivative 9 in 47.8% of nonresponders which was higher as compared to pretreatment (11%). Mix D-FISH signal pattern was found in around 20% of pretreatment and non-responder samples. Average interval from chronic phase to blast crisis and accelerated phase was respectively 3.5 and 18 months and accelerated to blast crisis was 16.5 months from the time of diagnosis. The follow-up duration of 31 patients responded to therapy was significantly higher (p=0.0001) as compared to 45 patients who did not respond to therapy. Variant D-FISH signal pattern was seen at the time of diagnosis in patient who responded to therapy as well as those patients who did not respond to therapy. Conclusion: This is the first study from India reporting deletion in ABL, BCR, or ABL-BCR on derivative 9 did not correlate with response to therapy
Trisomy 8 in leukemia: A GCRI experience
Trisomy of chromosome 8 is frequently reported in myeloid lineage
disorders and also detected in lymphoid neoplasms as well as solid
tumors suggesting its role in neoplastic progression in general. It is
likely to be a disease-modulating secondary event with underlying
cryptic aberrations as it has been frequently reported in addition to
known abnormalities contributing to clinical heterogeneity and
modifying prognosis. Here, we share our findings of trisomy 8 in
leukemia patients referred for diagnostic and prognostic cytogenetic
assessment. Total 60 cases of trisomy 8, as a sole anomaly or in
addition to other chromosomal aberrations, were reported (January
2005-September 2008). Unstimulated bone marrow or blood samples were
cultured, followed by GTG banding and karyotyping as per the ISCN 2005.
Patients with +8 were chronic myeloid leukemia (CML) (36), acute
myeloid leukemia (AML) (17), and acute lymphoblastic leukemia (ALL)
(7). In 7 patients, trisomy 8 was the sole anomaly, whereas in 6
patients +8 was in addition to normal clone, in 47 patients, the +8 was
in addition to t(9;22), t(15;17), and others, including 3 with
tetrasomy 8. Only one patient showed constitutional +8. The present
study will form the basis of further cumulative studies to correlate
potential differential effects of various karyotypic anomalies on
disease progression and survival following a therapeutic regime. To
unravel the role of extra 8 chromosome, constitutional chromosomal
analysis and uniparental disomy will be considered
Trisomy 8 in leukemia: A GCRI experience
Trisomy of chromosome 8 is frequently reported in myeloid lineage disorders and also detected in lymphoid neoplasms as well as solid tumors suggesting its role in neoplastic progression in general. It is likely to be a disease-modulating secondary event with underlying cryptic aberrations as it has been frequently reported in addition to known abnormalities contributing to clinical heterogeneity and modifying prognosis. Here, we share our findings of trisomy 8 in leukemia patients referred for diagnostic and prognostic cytogenetic assessment. Total 60 cases of trisomy 8, as a sole anomaly or in addition to other chromosomal aberrations, were reported (January 2005–September 2008). Unstimulated bone marrow or blood samples were cultured, followed by GTG banding and karyotyping as per the ISCN 2005. Patients with +8 were chronic myeloid leukemia (CML) (36), acute myeloid leukemia (AML) (17), and acute lymphoblastic leukemia (ALL) (7). In 7 patients, trisomy 8 was the sole anomaly, whereas in 6 patients +8 was in addition to normal clone, in 47 patients, the +8 was in addition to t(9;22), t(15;17), and others, including 3 with tetrasomy 8. Only one patient showed constitutional +8. The present study will form the basis of further cumulative studies to correlate potential differential effects of various karyotypic anomalies on disease progression and survival following a therapeutic regime. To unravel the role of extra 8 chromosome, constitutional chromosomal analysis and uniparental disomy will be considered